December 1975

Clinical Evaluation of a New Measles-Mumps-Rubella Trivalent Vaccine

Author Affiliations

From the Human Health Research Laboratories, Dow Chemical Company, Indianapolis (Drs Schwartz and Jackson), the Department of Medicine, Cedars of Lebanon Hospital, Miami, Fla (Drs Ehrenkranz and Ventura), the Department of Medicine, Medical College, University of Cincinnati (Dr Schiff), and the Department of Pediatrics, Coco Solo Hospital, Cristobal, Panama (Dr Walters).

Am J Dis Child. 1975;129(12):1408-1412. doi:10.1001/archpedi.1975.02120490026008

• In a series of clinical studies of a combined measles (Schwarz strain), mumps (Jeryl Lynn strain), and rubella (Cendehill strain) vaccine, 1,481 children received the vaccine or a placebo. The vaccine did not cause any significant reactions. The frequencies of mild, transient fever or rash or both in triple-susceptible vaccinees were similar to those that follow use of Schwarz strain measles vaccine alone. Measles, mumps, and rubella seroconversion rates in triple-susceptible vaccinees ranged from 95% to 100%. Geometric mean antibody titers were as high as those that usually result from use of these same virus strains as monovalent vaccines.

(Am J Dis Child 129:1408-1412, 1975)